Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CRAFTER: Preoperative ChemoRadiation and FOLFOXIRI for Rectal Cancer
NCT05358704Phase 2Suspended
- Sponsor
- Rutgers University
- Start
- May 2022
- Primary completion
- Dec 2027
- Modality
- DNA Intercalators/Alkylators, Irreversible Covalent Inhibitors, Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of capecitabine, oxaliplatin, folinic acid, irinotecan and fluorouracil in rectal cancer, sponsored by Rutgers University. Primary endpoint: Positron emission tomography at 4 years. Started May 2022; status: suspended.
02
Drugs
capecitabineoxaliplatinfolinic acidirinotecanfluorouracil
03
Conditions
rectal cancer
Beyond the preview
Go deeper on NCT05358704.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05358704.